Development

Johnson & Johnson's lumateperone ranks highest in adjunctive major depressive disorder network meta-analysis

Edited by Robert McTiernan··4 min read

Johnson & Johnson (NYSE: JNJ) reported that lumateperone (Caplyta) ranked highest across four efficacy measures in a network meta-analysis comparing FDA-approved atypical antipsychotics used as adjunctive depression therapy in adults with major depressive disorder. The indirect nature of the analysis means the findings carry the inherent limitations of any comparison drawn across separate placebo-controlled trials rather than head-to-head data.

The MDD network meta-analysis, presented as a late-breaking session at the 2026 Neuroscience Education Institute Spring Congress in Kissimmee, Florida, used a Bayesian statistical framework with a star-shaped network design to pool data from 10 randomized, double-blind, placebo-controlled trials in adults receiving antidepressant augmentation therapy for MDD.

The data on CAPLYTA adjunctive MDD efficacy

Lumateperone treatment produced the largest effect size among the five treatment nodes evaluated for all four prespecified efficacy outcomes versus antidepressant therapy (ADT) plus placebo. On the Montgomery-Åsberg Depression Rating Scale, the mean difference in change from baseline was -4.71 (95% credible interval -5.78 to -3.63). MADRS response — defined as at least a 50% reduction from baseline — favored lumateperone with an odds ratio of 2.33 (95% CrI 1.77 to 3.05), and MADRS remission showed an odds ratio of 2.22 (95% CrI 1.57 to 3.07). The Clinical Global Impression-Severity score change from baseline yielded a mean difference of -0.60 (95% CrI -0.74 to -0.46). In pairwise comparisons anchored to lumateperone, Caplyta was favored over all comparators on MADRS and CGI-S change from baseline, and over all but one comparator on response and remission.

The five agents evaluated were lumateperone, aripiprazole (Abilify), brexpiprazole (Rexulti), cariprazine (Vraylar), and quetiapine XR (Seroquel XR) — the full set of atypical antipsychotics currently carrying FDA approval as adjunctive therapy for MDD in adults. The common comparator across all nodes was ADT plus placebo, enabling indirect comparative estimates through the shared reference arm. Doses were pooled within treatments to reflect clinical decision-making at the treatment level rather than the dose level.

A differentiated tolerability profile

Beyond CAPLYTA efficacy rankings, the tolerability data may carry particular clinical weight. Lumateperone showed no statistically significant weight gain versus ADT plus placebo, with a mean weight change from baseline of -0.08 kg (95% CrI -0.30 to 0.13) and a 77% probability of superiority over placebo on that measure. For clinically meaningful weight gain — defined as an increase of 7% or more from baseline — the odds ratio was 0.41 (95% CrI 0.04 to 1.42), with a 94% probability of lower risk versus placebo. Lumateperone also held a 100% probability of superiority versus all comparators on mean weight change.

On akathisia, lumateperone was the only agent among the five evaluated that was statistically comparable to placebo plus ADT (OR 3.78; 95% CrI 0.40 to 17.17), though the wide credible interval reflects uncertainty in that estimate. The remaining four agents showed higher akathisia risk than placebo. Somnolence risk was elevated above placebo across all five treatments, including lumateperone (OR 5.90; 95% CrI 2.86 to 11.50); in pairwise comparisons, Caplyta showed comparable somnolence risk to two agents and higher risk versus two others.

The AllSci BriefSystematic R&D and deal news. Daily.

Weight gain and akathisia are among the most commonly cited tolerability concerns driving treatment discontinuation in antidepressant augmentation, which gives these findings some practical relevance for clinicians managing patients who have not achieved remission on an antidepressant alone. Only about one in three patients reaches remission with a first antidepressant, and response rates decline with each subsequent treatment step, leaving a substantial population cycling through adjunctive options.

Competitive positioning

Lumateperone's mechanism is multimodal and less D2-centric than most of its comparators in this analysis. While its exact mechanism of action in MDD remains incompletely characterized, it is thought to act through antagonism at central serotonin 5-HT2A receptors and partial agonism at dopamine D2 receptors, alongside downstream effects on glutamatergic neurotransmission — a profile that distinguishes it from agents such as aripiprazole and brexpiprazole, which are more classically framed as dopamine-serotonin activity modulators centered on D2 partial agonism.

Caplyta already holds FDA approval for adjunctive MDD treatment in adults, as well as for schizophrenia and bipolar depression. A supplemental new drug application covering long-term safety and efficacy data for delayed time to relapse in schizophrenia was recently approved. An active Phase III trial, NCT05850689, continues to recruit patients for lumateperone as adjunctive therapy in MDD, alongside several completed Phase III studies in the same setting.

The NMA was presented at the NEI Spring Congress and has not yet appeared in a peer-reviewed publication, which limits independent scrutiny of the methodology and underlying trial-level data. Publication in a reviewed journal would allow fuller assessment of the evidence synthesis, including the degree of heterogeneity across the 10 included trials and the sensitivity of the Bayesian model assumptions. J&J has not disclosed a specific timeline for peer-reviewed publication of these findings.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Spot something wrong? Report an issue with this article